Organisation paid for research Program year 2023 Source: CMS Open Payments

CCP Kids Way

Neither a doctor nor a teaching hospital

Research payments

$413,220

129 payments

Through program year 2023, CCP Kids Way is reported as receiving $413,220 in research payments, across 129 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $2,495 1
2022 Research $19,950 3
2021 Research $113,395 8
2020 Research $155,777 55
2019 Research $121,603 62

Breakdown

Who paid Research payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $410,725 128 payments
  2. Pfizer Inc. $2,495 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $207,260 21 payments
  2. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $85,402 18 payments
  3. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $80,155 7 payments
  4. A Phase 1, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of an Expanded Pneumococcal Conjugate Vaccine in Healthy Infants $16,666 1 payment
  5. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $16,320 60 payments
  6. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $2,795 12 payments
  7. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $2,495 1 payment
  8. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK) $973 2 payments
  9. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $779 3 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $375 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record